Now in private beta

Create | ready protocols
30-40% faster

AI-powered protocol generation, compliance validation, and amendment tracking for pharmaceutical and biotech clinical trials.

Request demo Try it out

GDPR Compliant

SOC 2 Controls

HIPAA-Ready

Enterprise Security

Welcome back, Sarah

You have 2 protocols in review and 3 issues to resolve

Total Protocols

Amendments

Compliance Issues

Team Members

New Protocol

Run Compliance

Amendments

Knowledge Base

Recent ProtocolsView all →

CAR-T Cell Therapy for Relapsed B-Cell Lymphoma

Phase 3, multicenter, randomized study

2h agoOncology

87%In Review

Novel Anti-PD1 Combination in Advanced NSCLC

Biomarker-driven adaptive design

1d agoOncology

92%Approved

First-in-Human Gene Therapy Study

Dose escalation with safety evaluation

3d agoGene Therapy

Draft

How It Works

From concept to compliant protocol

Four simple steps to create FDA-ready clinical trial protocols with AI assistance

Define Your Trial

Enter your therapeutic area, trial phase, study design, and key parameters. Our AI understands the context.

Therapeutic AreaOncology

Trial PhasePhase II

Study DesignRandomized, Double-Blind

Primary Endpoint

AI Generates Protocol

Our models analyze 500K+ trials and 200+ regulatory documents to generate a compliant first draft.

🧠

✓Analyzing similar trials...

✓Checking FDA guidance...

✓Generating sections...

✓Validating compliance...

Review & Refine

Collaborate with your team, accept AI suggestions, and see real-time compliance scoring as you edit.

✓ 94% Compliance Score

Export & Submit

Download in Word, PDF, or structured formats. Integrates with your existing clinical systems.

Word Doc

PDF

XML/JSON

CTMS

VeevaMedidataOracle

Inspired by Ancient Wisdom

Four Siblings. One Platform.

Just as Panacea's four siblings represented complete healthcare, Panaceon unites four essential tools into one comprehensive protocol platform.

Generate FDA ready protocols in minutes, not weeks

Our AI understands your therapeutic area, study design, and regulatory requirements. Input your trial parameters and receive a complete, compliant protocol draft—pulling from 500K+ clinical trials and 200+ FDA guidance documents.

Creation & Structure

Start generating

New Protocol

AI-Powered Generation

Therapeutic Area

Oncology - Solid Tumors

Trial Phase

Phase II

Study Design

Randomized, Double-Blind

Estimated Participants

240 patients

Automated checks against FDA, EMA & ICH guidelines

Stop manually cross-referencing 200+ regulatory documents. Our AI validates your protocol in real-time, identifies compliance gaps, and generates specific fixes with citations—so you submit right the first time.

Prevention of Errors

Check compliance

Compliance Report

Protocol ABC-2024-001

Compliance Score

✓FDA 21 CFR Part 312

✓ICH E6(R2) GCP Guidelines

!EMA Safety Reporting – 2 suggestions

✓ICH E8(R1) Study Design

3M+ documents at your fingertips with semantic search

Ask questions in plain English and get instant answers from FDA guidance, EMA guidelines, ClinicalTrials.gov, PubMed, ChEMBL, and more. Our vector search understands context—not just keywords.

Healing Knowledge Gaps

Explore knowledge base

Knowledge Search

Semantic AI-Powered

📄 FDA Guidance 2023

Non-Small Cell Lung Cancer: Eligibility Criteria

Patients should have histologically confirmed NSCLC with measurable disease per RECIST v1.1...

🔬 ClinicalTrials.gov

NCT04821674 - Phase II NSCLC Study

Key eligibility: EGFR mutation-positive, prior TKI therapy, ECOG PS 0-1...

📚 PubMed

Best Practices for NSCLC Trial Design (2024)

Modern NSCLC trials increasingly incorporate biomarker-driven enrollment...

Predict downstream effects before they become costly

The only platform that shows you exactly what changes when you modify your protocol. Our AI maps dependencies across sections and regulatory documents—so you understand the full impact before making a change.

Recuperation & Evolution

Analyze amendments

Amendment Analysis

Impact Assessment

v2.1 → v2.2

Medium Impact

Section 5.2 - Inclusion Criteria

Modified: ECOG PS 0-1 → ECOG PS 0-2

Section 7.4 - Safety Monitoring

Added: Cardiac monitoring every 2 weeks

Ripple Effects Detected

• Affects: Schedule of Assessments, Sample Size, IB Update

Create | ready protocols30-40% faster